Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis

Abstract EN

Background.

The expression of the cancerous inhibitor protein phosphatase 2A (CIP2A) appears to be predictive of the prognosis of various solid tumors.

However, the association between this protein and the risk of esophagogastric junction adenocarcinoma (EGJA) remains unclear.

We investigated CIP2A expression and its clinical significance in EGJA and conducted a meta-analysis to explore the relationship between CIP2A and the prognosis of patients with solid tumors.

Methods.

Immunohistochemistry (IHC) was performed to detect the expression of CIP2A in EGJA.

Kaplan-Meier estimation, Cox analysis, and ROC curves were performed to analyze the survival of patients and the prognostic factors.

In the meta-analysis, we searched relevant publications in several widely used databases and used 15 studies (2348 patients).

Results.

IHC demonstrated that CIP2A was elevated in EGJA and correlated with poor survival as an independent indicator.

It could forecast the survival more precisely when combined with the grade, which is another independent prognosis marker of EGJA.

Meta-analysis demonstrated that the associations between the expression of CIP2A and the prognosis were detected for overall survival (HR=1.98, 95%CI=1.69‐2.32), disease-specific survival (HR=1.72, 95%CI=1.50‐1.97), and time to tumor progression (pooled HR=1.95, 95%CI=1.56‐2.43).

Conclusion.

High expression of CIP2A was a poor indicator of the prognosis of EGJA, and CIP2A may be a new biomarker for the diagnosis and treatment of EGJA.

The meta-analysis suggested that CIP2A expression can be a predictive marker of overall survival, disease-specific survival, and time to tumor progression in patients with solid tumors.